Experimental drug that relieves the effects of breast cancer treatment

The results of experiments in their last stages have shown that hot flashes and night sweats suffering from breast cancer survivors during hormone inhibing years can be mitigated by a non -hormonal experimental drug developed by the US company “Bayer”. The experiment participants grew crops as a result of estrogen and progesterone, similar to two -thirds of breast cancer patients in general. The purpose of the so -called hormonal therapy is to prevent the production of these hormones, causing annoying menopause symptoms. The most effective way to relieve these symptoms in healthy women is to compensate for hormones, but these hormones help with crops growth. In an experiment that lasted about a year and included 474 breast cancer patients, suffering from hot flashes daily due to hormone inhibitors, 316 of them received the medicine ‘Einzanitant’ produced by ‘Bayer’, while 158 of them received an imaginary remedy. The researchers reported during a recent meeting of oncologists and in the magazine ‘New England’ that I reached more than 70% of those who took the drug ‘Einzanitant’ within three months, about a decrease of at least 50% in medium to severe hot flashes, compared to about 36% of the place of misleading therapy. The medicine also has a significant improvement in the quality of sleep and the quality of life after a significant menopause by the 12th week. Dr. Fatima Kardozo, from the Champalaud Medical Center in Lisbon, which led the research team, said: “It is important to treat symptoms associated with blood vessels because it can negatively affect the quality of life and drive women to stop the treatment of breast cancer prematurely.” The drug “Einzanitant” belongs to a new category of medicine aimed at the biological nerve mechanisms in the brain that participates in the cause of hot flashes and night sweats. Bayer awaits the approval of the US Food and Drug Administration and the European Medicine Agency.